Endurant Capital Management’s PTC Therapeutics PTCT Stock Holding History

Endurant Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-53,247	Closed	-$2.58M	–	53
2023 Q1	$2.58M	Buy	53,247 +35,361	+198%	+$1.62M	1.32%	21
2022 Q4	$683K	Buy	+17,886	New	+$744K	0.28%	42
2020 Q3	–	Sell	-19,677	Closed	-$998K	–	71
2020 Q2	$998K	Buy	+19,677	New	+$967K	0.05%	49
2019 Q2	–	Sell	-16,903	Closed	-$636K	–	71
2019 Q1	$636K	Buy	+16,903	New	+$568K	0.25%	56
2016 Q1	–	Sell	-14,800	Closed	-$480K	–	89
2015 Q4	$480K	Sell	14,800 -8,200	-36%	-$241K	0.16%	70
2015 Q3	$614K	Sell	23,000 -1,100	-5%	-$47K	0.21%	65
2015 Q2	$1.16M	Buy	+24,100	New	+$1.41M	0.34%	61

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Endurant Capital Management's PTCT Position: Q2 2023 in Review

Endurant Capital Management sold out of PTC Therapeutics (PTCT) in Q2 2023, closing a stake of 53,247 shares — an estimated $2.58M sold.

Endurant Capital Management first reported a position in PTCT in Q2 2015 and held it in 7 quarters. The position peaked at $2.58M in Q1 2023. 204 funds tracked by Wall St. Rank hold PTCT as of Q2 2023.

Endurant Capital Management reported no remaining PTC Therapeutics position as of Q2 2023 after selling out during the quarter.
Endurant Capital Management sold 53,247 PTC Therapeutics shares in Q2 2023, an estimated $2.58M.
Endurant Capital Management first reported a position in PTC Therapeutics in Q2 2015 and held it in 7 quarters.
Endurant Capital Management's PTC Therapeutics position peaked at $2.58M in Q1 2023.
204 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2023.

Based on Endurant Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.